Respiratory Disease News and Research RSS Feed - Respiratory Disease News and Research

Flu jab linked to reduced hospitalisation risk in heart failure patients

Flu jab linked to reduced hospitalisation risk in heart failure patients

The flu jab is associated with a reduced risk of hospitalisation in patients with heart failure, according to research presented today in a late breaking trial session at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure. [More]
Overnight extubations in ICU patients linked to higher mortality

Overnight extubations in ICU patients linked to higher mortality

Adult patients who were admitted to U.S. intensive care units had higher mortality if they were extubated overnight. The results reported at the ATS 2016 International Conference may discourage hospital administrators from expanding the practice of overnight extubations in ICUs, which the lead author noted are rapidly being transformed to provide continuity of care. [More]
American Thoracic Society and Sunovion release landmark survey of pulmonologists’ attitudes and practices with inhalation devices for COPD

American Thoracic Society and Sunovion release landmark survey of pulmonologists’ attitudes and practices with inhalation devices for COPD

The American Thoracic Society (ATS) and Sunovion Pharmaceuticals Inc. (Sunovion) today announced the results of a survey of pulmonologists and pulmonology fellows to determine physicians’ knowledge, attitudes, and practices related to chronic obstructive pulmonary disease (COPD) management, with particular attention to the use of hand-held small volume nebulizers. A small volume nebulizer is a device powered by air that aerosolizes medications for delivery to patients. [More]
Medical error is the third biggest cause of death in the US, according to experts

Medical error is the third biggest cause of death in the US, according to experts

After analyzing medical death rate data over an eight year period, Johns Hopkins researchers found that more than 250,000 people die in the U.S each year as a result of medical error, making it the third biggest cause of death after heart disease and cancer. [More]
Green vegetation near homes plays important role in reducing mortality

Green vegetation near homes plays important role in reducing mortality

Women live longer in areas with more green vegetation, according to new research funded by the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health. Women with the highest levels of vegetation, or greenness, near their homes had a 12 percent lower death rate compared to women with the lowest levels of vegetation near their homes. The results were published Apr. 14, 2016 in the journal Environmental Health Perspectives. [More]
Cigarette smoking, viral infections may reduce effectiveness of COPD symptom-reliever medication

Cigarette smoking, viral infections may reduce effectiveness of COPD symptom-reliever medication

New study backs up observations in Chronic Obstructive Pulmonary Disease (COPD) patients showing reduced effectiveness of symptom-reliever medication (β2-adrenoceptor agonists) in flare-ups linked to cigarette smoking and infection with viruses such as influenza. [More]
Study finds evidence of lung function abnormalities in light-use hookah smokers

Study finds evidence of lung function abnormalities in light-use hookah smokers

A study of light-use hookah or waterpipe smokers found evidence of lung function abnormalities, including marked changes in cells lining the airways. The study, "Pulmonary Abnormalities in Young, Light-use Waterpipe (Hookah) Smokers," was published recently in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
N-KICS tool helps describe intensity of nursing care for children with CMC

N-KICS tool helps describe intensity of nursing care for children with CMC

Recent medical advances have resulted in increased survival of children with complex medical conditions (CMC), such as cerebral palsy, complex chromosomal anomalies, major congenital heart diseases and respiratory disease. [More]
Teach-to-goal inhaler education improves mastery of life-saving technique

Teach-to-goal inhaler education improves mastery of life-saving technique

A rescue inhaler can be a lifesaver during an asthma or COPD flareup, but using a rescue inhaler is complicated and misuse is common, putting patients' lives at risk. An education strategy, called teach-to-goal, may help patients use their inhalers properly during these critical times, according to research published online ahead of print in the American Thoracic Society journal Annals of the American Thoracic Society. [More]
Public health benefits of using more recycled water

Public health benefits of using more recycled water

Expanding the use of recycled water would reduce water and energy use, cut greenhouse gas emissions and benefit public health in California -- which is in the midst of a severe drought -- and around the world. [More]
Omalizumab drug can be better targeted to treat people with severe asthma

Omalizumab drug can be better targeted to treat people with severe asthma

Around five million people in the UK are currently being treated for asthma. Of these, a quarter of a million are unable to get good control of their condition, resulting in frequent, severe, or even life-threatening attacks. A new study brings hope to these patients by investigating whether the drug Omalizumab can be better targeted. [More]
Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. [More]
Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy designation to PKC412 (midostaurin). PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy. [More]
WRAIR begins Phase 1 clinical trial to evaluate MERS vaccine candidate

WRAIR begins Phase 1 clinical trial to evaluate MERS vaccine candidate

The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS). [More]
Five centres awarded status of NHS Innovation Test Beds

Five centres awarded status of NHS Innovation Test Beds

NHS England has announced the five centres that have been awarded the status of Innovation Test Beds in which new approaches to healthcare provision will be assessed and adopted and two centres for the adoption of the Internet of Things (IoT) in healthcare. [More]
Diet rich in fiber may reduce risk of developing lung disease

Diet rich in fiber may reduce risk of developing lung disease

A diet rich in fiber may not only protect against diabetes and heart disease, it may reduce the risk of developing lung disease, according to new research published online, ahead of print in the Annals of the American Thoracic Society. [More]
Adults with long-term exposure to ozone face increased risk of respiratory and cardiovascular deaths

Adults with long-term exposure to ozone face increased risk of respiratory and cardiovascular deaths

Adults with long-term exposure to ozone (O3) face an increased risk of dying from respiratory and cardiovascular diseases, according to the study "Long-Term Ozone Exposure and Mortality in a Large Prospective Study" published online ahead of print in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). [More]
UA researchers find genetic mutations associated with respiratory disease

UA researchers find genetic mutations associated with respiratory disease

Asthma affects more than 278 million people worldwide and can lead to serious consequences later in life. While current approved therapies address symptoms, they do not halt disease progression. [More]

Critically ill patients exposed to higher ozone levels more likely to develop ARDS

Critically ill patients who are exposed to higher daily levels of ozone are more likely to develop acute respiratory disease syndrome (ARDS), according to a new study published online ahead of print in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. [More]
Advertisement